Q2
DHR — Q2 2026 Financial Report Analysis
Danaher Q2 2026: sales rose 5.5% to $6.27B with core growth of 3.0% (4.5% excluding respiratory testing); GAAP EPS jumped to $1.23 mainly because Q2 2025 carried a $432M write-down, adjusted EPS rose ~8% to $1.94, and full-year adjusted EPS guidance was raised to $8.45–$8.60 after the $9.8B Masimo deal closed.